C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes

Summary

Non-specific markers of inflammation such as C-reactive protein (CRP) are associated statistically with an increased risk of atherosclerosis through mechanisms that have not yet been fully elucidated.We investigated the effects of CRP on several aspects of human monocyte biology, a cell type involved in the initiation and progression of atherosclerosis. Blood monocytes isolated from healthy men and premenopausal women (n=9/group) were exposed to purified CRP (25 μg/ml) for 12 hours. Changes in gene expression were analyzed using a custom-made array containing oligonucleotide sequences of 250 genes expressed by activated monocytes and confirmed by quantitative PCR. CRP increased significantly the expression of the cytokines interleukin (IL)-1α, IL-1β and IL-6, and the chemokines GRO-α, GRO-β and IL-8. CRP also displayed anti-inflammatory effects through upregulation of liver X receptor (LXR) α and activin receptor expression, and down-regulation of alpha 2-macroglobulin expression. Increased LXRα mRNA expression in both monocytes and the monocytic cell lineTHP-1 was associated with increased LXRα protein expression and nuclear translocation, as well as increased ABCA1 mRNA expression, a target gene of LXRα. Western Blot analysis revealed CRP-induced nuclear translocation of NF-κB and activation of p42/44, MAP and Akt kinases. CRP-induced LXRá mRNA expression was inhibited by anti-CD64 (FcγRI) antibodies and by p42/44 and PI3 kinase inhibitors. This hypothesis-generating study demonstrates that CRP modulates the expression of genes that contribute to both pro- and anti-inflammatory responses in human monocytes. Among these novel anti-inflammatory effects, we show clearly that CRP activates the LXRα pathway.

Keywords

Atherosclerosis - inflammation - C-reactive protein - liver X receptors - microarrays

Notes

^* These authors contributed equally to this work.

• References

• 1 Faxon DP, Creager MA, Smith SC. Jr. et al. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004; 109: 2595-604.
• 2 Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
• 3 Binder CJ, Chang MK, Shaw PX. et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226.
• 4 Faxon DP, Fuster V, Libby P. et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109: 2617-2625.
• 5 Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004; 109: 2818-2825.
• 6 Wang TJ, Gona P, Larson MG. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
• 7 Pearson TA, Mensah GA, Alexander RW. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centersfor Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
• 8 Asanuma Y, Oeser A, Shintani AK. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
• 9 Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004; 31: 1095-1097.
• 10 Lowbeer C, Gutierrez A, Gustafsson SA. et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant 2002; 17: 2178-2183.
• 11 Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
• 12 Torzewski M, Rist C, Mortensen RF. et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
• 13 Mold C, Du Clos TW. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fcγreceptors. J Immunol 2006; 176: 7598-7604.
• 14 Paffen E, De Maat MP. C-reactive protein in atherosclerosis: A causal factor?. Cardiovasc Res 2006; 71: 30-39.
• 15 Baugh LR, Hill AA, Brown EL. et al. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 2001; 29: E29.
• 16 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
• 17 Chen CH, Seguin-Devaux C, Burke NA. et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 2003; 197: 1689-1699.
• 18 Khreiss T, Jozsef L, Potempa LA. et al. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110: 2713-2720.
• 19 Khreiss T, Jozsef L, Potempa LA. et al. Loss of pentameric symmetry in C-reactive protein induces interleukin- 8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 2005; 97: 690-697.
• 20 Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol 2001; 31: 3475-3483.
• 21 Stein MP, Edberg JC, Kimberly RP. et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000; 105: 369-376.
• 22 Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25: 1225-1230.
• 23 Liu C, Wang S, Deb A. et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 2005; 97: 135-143.
• 24 Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993.
• 25 Mold C, Rodriguez W, Rodic-Polic B. et al. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002; 169: 7019-7025.
• 26 Williams TN, Zhang CX, Game BA. et al. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcγRII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24: 61-66.
• 27 Szmitko PE, Wang CH, Weisel RD. et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917-1923.
• 28 Szmitko PE, Wang CH, Weisel RD. et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 2041-2048.
• 29 Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
• 30 Galve-de Rochemonteix B, Wiktorowicz K, Kushner I. et al. C-reactive protein increases production of IL-1α, IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages. J Leukoc Biol 1993; 53: 439-445.
• 31 Gerszten RE, Garcia-Zepeda EA, Lim YC. et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-723.
• 32 Tilg H, Vannier E, Vachino G. et al. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1βsynthesis by human peripheral blood mononuclear cells. J Exp Med 1993; 178: 1629-1636.
• 33 Hagiwara H, Mitsumata M, Yamane T. et al. Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. Circulation 1998; 98: 2584-2590.
• 34 Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823.
• 35 Nagase H. Activation mechanisms of matrix metalloproteinases. Biological Chemistry 1997; 378: 151-160.
• 36 Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-481.
• 37 Szalai AJ, Nataf S, Hu XZ. et al. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002; 168: 5792-5797.
• 38 Taylor AW, Mortensen RF. Effect of α2-macroglobulin on cytokine-mediated human C-reactive protein production. Inflammation 1991; 15: 61-70.
• 39 Bunton DC, Petrie MC, Hillier C. et al. The clinical relevance of adrenomedullin: a promising profile?. Pharmacol Ther 2004; 103: 179-201.
• 40 Temmesfeld-Wollbruck B, Hocke AC, Suttorp N. et al. Adrenomedullin and endothelial barrier function. Thromb Haemost 2007; 98: 944-951.
• 41 Niemann-Jonsson A, Dimayuga P, Jovinge S. et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol 2000; 20: 2205-2211.
• 42 Bisoendial RJ, Kastelein JJ, Levels JH. et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
• 43 Joseph SB, Castrillo A, Laffitte BA. et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219.
• 44 Prufer K, Boudreaux J. Nuclear localization of liver X receptor alpha and beta is differentially regulated. J Cell Biochem 2007; 100: 69-85.
• 45 Watanabe Y, Jiang S, Takabe W. et al. Expression of the LXRalpha protein in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25: 622-627.
• 46 Chen M, Li W, Wang N. et al. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am J Physiol Cell Physiol 2007; 292: C1493-501.
• 47 Castrillo A, Joseph SB, Marathe C. et al. Liver X receptor- dependent repression of matrix metalloproteinase- 9 expression in macrophages. J Biol Chem 2003; 278: 10443-1049.
• 48 Bhakdi S, Torzewski M, Paprotka K. et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109: 1870-1876.
• 49 Blaschke F, Takata Y, Caglayan E. et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res 2006; 99: e88-99.
• 50 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
• 51 Kovacs A, Tornvall P, Nilsson R. et al. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007; 104: 13768-13773.
• 52 Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197.
• 53 Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci USA 1997; 94: 2575-2580.
• 54 Zouki C, Beauchamp M, Baron C. et al. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997; 100: 522-529.
• 55 Sander K, Horn CS, Briesenick C. et al. High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study. Stroke 2007; 38: 2881-2886.
• 56 Rutter MK, Meigs JB, Sullivan LM. et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.